Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 plus letrozole versus placebo plus letrozole in first-line HR-positive, HER2-negative advanced breast cancer
NL-OMON55670Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ribociclib and letrozole, sponsored by Novartis. Started Jun 2014; status: active, not recruiting.
02
Drugs
ribociclibletrozole
Beyond the preview
Go deeper on NL-OMON55670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55670.